Elizabeth A. Galloway
Known title: EVP and CHROCIK: 0001748182
Associated companies
Transaction History
| BCO | ▼ Sell | Tax Withholding | 3,240 | $306K | 6/30/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 341 | $43K | 3/3/2026 | View on chart |
| BCO | ▲ Buy | Grant | 1,816 | $0 | 3/2/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 325 | $38K | 3/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 16,712 | $2.2M | 2/18/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 6,626 | $860K | 2/18/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 3,241 | $289K | 6/30/2025 | View on chart |
| BCO | ▲ Buy | Grant | 2,596 | $0 | 3/3/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 369 | $35K | 3/1/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 3,242 | $332K | 6/30/2024 | View on chart |
| BCO | ▲ Buy | Grant | 2,476 | $0 | 3/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 24,699 | $0 | 5/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.